Cellyan Biotechnology Co., Ltd cash flow statement

In fiscal 2026, Cellyan Biotechnology Co., Ltd's operations generated −$751,602 of cash; it spent $35,470 on capital projects, leaving free cash flow of −$787,072.

Cash flow statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cellyan Biotechnology Co., Ltd: cash flow statement, annual
Fiscal year	2023Mar 2023	2024Mar 2024	2025Mar 2025	2026Mar 2026
Cash from operations	1,727	−394	569	−752
Depreciation and amortisation	74	58	66	79
Capital spending	115	53	70	35
Free cash flow	1,612	−447	499	−787

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: COSM vs HKPD HKPD vs YI HKPD vs HSIC

More: Health Care Distributors stocks compared, Health Care sector, rankings of US companies

Figures from Cellyan Biotechnology Co., Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cellyan Biotechnology Co., Ltd.